« Older Entries
Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
Amolyt Pharma announces research collaboration with PeptiDream
The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF